Mark Sterling, MD
Gastroenterology · Pittsfield, MANPI 1306822069
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $799 and has fallen 58.7% since, to $330 in 2025.
Across 56 payments — averaging $28.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$352
- Johnson & Johnson$295
- Cook Medical LLC$266
- AbbVie$217
- Madrigal Pharmaceuticals$208
- Takeda Pharmaceuticals U.S.A., Inc.$83
- plus $162 from 5 others
What the payments were for
- Food & beverage$1,583100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $352 |
| Johnson & Johnson | 16 | $295 |
| Cook Medical LLC | 4 | $266 |
| AbbVie | 11 | $217 |
| Madrigal Pharmaceuticals | 4 | $208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $83 |
| Ipsen Biopharmaceuticals, Inc | 2 | $70 |
| UCB, Inc. | 2 | $32 |
| Medtronic | 1 | $28 |
| Pfizer | 1 | $18 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,583 in reported general payments places this provider in the 55th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Entecavir | 12 | $4,932 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 30 | $1,905 |
| Pantoprazole Sodium | 61 | $940 |
| Omeprazole | 90 | $804 |
| Dicyclomine Hcl | 15 | $346 |
| Ondansetron OdtOndansetron | 12 | $240 |
| Sucralfate | 12 | $206 |
| Famotidine | 34 | $138 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Pittsfield
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- John LeungBoston$682K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
- Carlo TraversoBoston$447K
- Razvan ArsenescuMedford$385K
- Steven FineFramingham$259K
- Tyler BerzinBoston$215K
- Khaldoon KhirfanBurlington$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.